Since March 30 QDEL (Nasdaq) has been increasing from $95 to $180.91. That’s an almost double change within one and a half months. Lyra SARS-CoV-2 Assay is the main flagship of Quidel that helps other biotech firms to create a vaccine to fight the coronavirus pandemic. Besides that, there are a lot of molecular diagnostics offered by the corporation. The demand for its products will, of course, increase the revenue thus long term focused investors seek to receive dividends from the growing stock as the corporation has positively grown earnings.
The total assets and equity have increased significantly despite the liabilities surged a bit in Q1 2020 report. The total stock volume almost doubled since the outbreak. There is still a huge space in QDEL’s opportunity while the COVID-19 continues to spread.